» Articles » PMID: 32107449

Level of Obesity is Directly Associated with the Clinical and Functional Consequences of Knee Osteoarthritis

Overview
Journal Sci Rep
Specialty Science
Date 2020 Feb 29
PMID 32107449
Citations 86
Authors
Affiliations
Soon will be listed here.
Abstract

Obesity is one of the most important risk factors of knee osteoarthritis (KOA), but its impact on clinical and functional consequences is less clear. The main objective of this cross-sectional study was to describe the relation between body mass index (BMI) and clinical expression of KOA. Participants with BMI ≥ 25 kg/m and KOA completed anonymous self-administered questionnaires. They were classified according to BMI in three groups: overweight (BMI 25-30 kg/m), stage I obesity (BMI 30-35 kg/m) and stage II/III obesity (BMI ≥ 35 kg/m). The groups were compared in terms of pain, physical disability, level of physical activity (PA) and fears and beliefs concerning KOA. Among the 391 individuals included, 57.0% were overweight, 28.4% had stage I obesity and 14.6% had stage II/III obesity. Mean pain score on a 10-point visual analog scale was 4.3 (SD 2.4), 5.0 (SD 2.6) and 5.2 (SD 2.3) with overweight, stage I and stage II/III obesity, respectively (p = 0.0367). The mean WOMAC function score (out of 100) was 36.2 (SD 20.1), 39.5 (SD 21.4) and 45.6 (SD 18.4), respectively (p = 0.0409). The Knee Osteoarthritis Fears and Beliefs Questionnaire total score (KOFBEQ), daily activity score and physician score significantly differed among BMI groups (p = 0.0204, p = 0.0389 and p = 0.0413, respectively), and the PA level significantly differed (p = 0.0219). We found a dose-response relation between BMI and the clinical consequences of KOA. Strategies to treat KOA should differ by obesity severity. High PA level was associated with low BMI and contributes to preventing the clinical consequences of KOA.

Citing Articles

The Outcome of Post-Surgical Hip Prosthesis Rehabilitation: Results from a Monocentric Cohort Study.

Garifi M, Cartocci A, Guarducci G, Praino F, Sanguineti I, Cristiani S J Clin Med. 2025; 14(4).

PMID: 40004806 PMC: 11856184. DOI: 10.3390/jcm14041276.


The Expression Level of SOX Family Transcription Factors' mRNA as a Diagnostic Marker for Osteoarthritis.

Baran K, Brzezianska-Lasota E, Kryczka J, Boncela J, Czechowska A, Kopacz K J Clin Med. 2025; 14(4).

PMID: 40004707 PMC: 11856735. DOI: 10.3390/jcm14041176.


The Efficacy of Piascledine in Alleviating Symptoms and Its Impact on Blood Lipid Levels and body Mass Index in Patients with Knee Osteoarthritis.

Phan H, Huynh C, La P, Pham K, Vo P, Vo T Med Arch. 2025; 78(4):296-301.

PMID: 39981153 PMC: 11838829. DOI: 10.5455/medarh.2024.78.296-301.


Knee osteoarthritis among adults in Al Madam city, Sharjah: unrevealing the prevalence and predisposing factors: a cross-sectional study.

Qureshi S, Girish S, Kandakurti P, Amaravadi S, Hazari A BMC Musculoskelet Disord. 2025; 26(1):142.

PMID: 39939935 PMC: 11817559. DOI: 10.1186/s12891-025-08386-5.


Development and validation of a new nomogram for self-reported OA based on machine learning: a cross-sectional study.

Chen J, Zheng Q, Lan Y, Li M, Lin L Sci Rep. 2025; 15(1):827.

PMID: 39755736 PMC: 11700110. DOI: 10.1038/s41598-024-83524-y.


References
1.
Bitton R . The economic burden of osteoarthritis. Am J Manag Care. 2009; 15(8 Suppl):S230-5. View

2.
Bellamy N, BUCHANAN W, Goldsmith C, Campbell J, Stitt L . Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988; 15(12):1833-40. View